| 2,005 | 79 | 110 |
| 下载次数 | 被引频次 | 阅读次数 |
肠道微生态与多种疾病的发生和治疗有关,从肠道微生态的角度研究肥胖、炎症性肠病、功能性胃肠病、代谢综合征、肝硬化等疾病,可为其诊治方法及发病机制研究提供新的思路。证候表型研究是中医学术研究的核心内容,证候客观化研究一直难以取得突破。认为证候表型如脾虚证、湿热证的发生存在着肠道微生态的失调,采用相应的治法如健脾、清热化湿等治疗后,在证候得到改善的同时肠道微生态亦得到恢复。提出从肠道微生态的角度研究脾虚证、湿热证与其相关性,对于深化证候生物学基础研究及揭示辨证论治的科学内涵具有重要意义。
Abstract：Intestinal tract micro ecology relates to the occurrence and treatment of a variety of diseases. Research of obesity,inflammatory bowel disease,functional gastrointestinal disorder,metabolic syndrome and liver cirrhosis from the aspect of intestinal tract micro ecology may provide new ideas for diagnosing and treating methods,as well as pathogenesis study. Syndrome phenomics study is the core content of Chinese medicine academic research. It is difficult to make a breakthrough in objectification research. The authors think that the occurrence of syndrome phenomics,such as spleen deficiency syndrome and dampness-heat syndrome,show the imbalance in intestinal tract micro ecology. After therapy adopting the corresponding treatment methods,such as invigorating spleen,clearing heat and eliminating dampness,the syndrome could be improved. Meanwhile,intestinal tract micro ecology could also be recovered. The authors put forward that researching the correlation between spleen deficiency syndrome,dampness-heat syndrome and intestinal tract micro ecology are significant for deepening basic research in syndrome biology and revealing the scientific connotation of treatment based on syndrome differentiation.
[1]吕爱平,张弛,吕诚,等.疾病诊断和证候分类:整合及未来发展[J].世界科学技术-中医药现代化,2016,18(10):1626-1630.
[2]杨化冰,邹小娟,孔明望,等.肠道微生态与传统中医思想内涵[J].中医杂志,2017,58(12):1070-1072.
[3]QIN J,LI R,RAES J,et al.A human gut microbial gene catalogue established by metagenomic sequencing[J].Nature,2010,464(7285):59-65.
[4]ZHAO L.Genomics:the tale of our other genome[J].Nature,2010,465(7300):879-880.
[5]CLEMENTE JC,URSELL LK,PARFREY LW,et al.The impact of the gut microbiota on human health:an integrative view[J].Cell,2012,148(6):1258-1270.
[6]BIEDERMANN L,ROGLER G.The intestinal microbiota:its role in health and disease[J].Eur J Pediatr,2015,174(2):151-167.
[7]KELLY CR,KAHN S,KASHYAP P,et al.Update on fecal microbiota transplantation 2015:indications,methodologies,mechanisms,and outlook[J].Gastroenterology,2015,149(1):223-237.
[8]TURNBAUGH PJ,LEY RE,MAHOWALD MA,et al.An obesity-associated gut microbiome with increased capacity for energy harvest[J].Nature,2006,444(7122):1027-1031.
[9]DIBAISE JK,ZHANG H,CROWELL MD,et al.Gut microbiota and its possible relationship with obesity[J].Mayo Clin Proc,2008,83(4):460-469.
[10]CHANG CJ,LIN CS,LU CC,et al.Ganoderma lucidum reduces obesity in mice by modulating the composition of the gut microbiota[J].Nat Commun,2015,6:7489.doi:10.1038/ncomms7489.
[11]VILLANUEVA-MILLN MJ,PREZ-MATUTE P,OTEO JA.Gut microbiota:a key player in health and disease.A review focused on obesity[J].J Physiol Biochem,2015,71(13):509-525.
[12]GHOURI YA,RICHARDS DM,RAHIMI EF,et al.Systematic review of randomized controlled trials of probiotics,prebiotics,and synbiotics in inflammatory bowel disease[J].Clin Exp Gastroenterol,2014,7:473-487.doi:10.2147/CEG.S27530.
[13]MOAYYEDI P,SURETTE MG,KIM PT,et al.Fecal microbiota transplantation induces remission in patients with active ulcerative colitis in a randomized controlled trial[J].Gastroenterology,2015,149(1):102-109.
[14]YOSHIMATSU Y,YAMADA A,FURUKAWA R,et al.Effectiveness of probiotic therapy for the prevention of relapse in patients with inactive ulcerative colitis[J].World J Gastroenterol,2015,21(19):5985-5994.
[15]LEE KN,LEE OY.Intestinal microbiota in pathophysiology and management of irritable bowel syndrome[J].World J Gastroenterol,2014,20(27):8886-8897.
[16]HUNGIN AP,MULLIGAN C,POT B,et al.Systematic review:probiotics in the management of lower gastrointestinal symptoms in clinical practice:an evidence-based international guide[J].Aliment Pharmacol Ther,2013,38(8):864-886.
[17]YOON JS,SOHN W,LEE OY,et al.Effect of multispecies probiotics on irritable bowel syndrome:a randomized,double-blind,placebo-controlled trial[J].J Gastroenterol Hepatol,2014,29(1):52-59.
[18]WHELAN K.Probiotics and prebiotics in the management of irritable bowel syndrome:a review of recent clinical trials and systematic reviews[J].Curr Opin Clin Nutr Metab Care,2011,14(6):581-587.
[19]MENEES SB,MANEERATTANNAPORN M,KIM HM,et al.The efficacy and safety of rifaximin for the irritable bowel syndrome:a systematic review and meta-analysis[J].Am J Gastroenterol,2012,107(1):28-35.
[20]LAU E,CARVALHO D,FREITAS P.Gut Microbiota:association with NAFLD and metabolic disturbances[J].Biomed Res Int,2015,2015:979515.doi:10.1155/2015/979515.
[21]ABDUL-HAI A,ABDALLAH A,MALNICK SD.Influence of gut bacteria on development and progression of non-alcoholic fatty liver disease[J].World J Hepatol,2015,7(12):1679-1684.
[22]FESTI D,SCHIUMERINI R,EUSEBI LH,et al.Gut microbiota and metabolic syndrome[J].World J Gastroenterol,2014,20(43):16079-16094.
[23]陈燕飞.肝硬化患者肠道微生态研究:从结构到功能[D].杭州:浙江大学,2013.
[24]QIN N,YANG F,LI A,et al.Alterations of the human gut microbiome in liver cirrhosis[J].Nature,2014,513(7516):59-64.
[25]XU J,MA R,CHEN LF,et al.Effects of probiotic therapy on hepatic encephalopathy in patients with liver cirrhosis:an updated meta-analysis of six randomized controlled trials[J].Hepatobiliary Pancreat Dis Int,2014,13(4):354-360.
[26]《中华消化杂志》编委会.肠道菌群失调诊断治疗建议[J].中华消化杂志,2009,29(5):335-337.
[27]任平,夏天,李平,等.脾虚腹泻患者肠道菌群的研究[J].中医杂志,1992,33(6):33-34.
[28]卢林,杨景云,李丹红.健脾渗湿汤对脾虚湿盛泄泻患者肠道微生态及舌部菌群影响的研究[J].中国微生态学杂志,2007,19(5):439-441.
[29]刘佳,彭颖,张硕颖,等.老年脾虚患者肠道菌群16Sr DNA变性梯度凝胶电泳分析[J].中华中医药杂志,2010,25(10):1566-1569.
[30]任平,夏天,黄熙,等.大鼠脾虚模型的肠道菌群研究[J].陕西中医,1991,12(9):427-428.
[31]鞠宝玲,陆叶,唐小云,等.四君子汤及其纳米制剂对微生态失调小鼠的调整作用[J].中国微生态学杂志,2007,19(1):6-8.
[32]彭颖,金晶,杨静玉,等.3种健脾补气方药对脾气虚证大鼠肠道菌群的影响[J].中国中药杂志,2008,33(21):2530-2534.
[33]王卓,彭颖,李晓波.四君子汤对两种脾虚模型大鼠肠道菌群紊乱的影响[J].中国中西医结合杂志,2009,29(9):825-829.
[34]舒青龙,王萍,封勇,等.理中汤对抗生素相关性腹泻模型构建中肠道菌群变化的影响[J].中国实验方剂学杂志,2015,21(21):82-87.
[35]陈学习,张英杰,李美霞,等.脾虚证与免疫系统关系研究概况与思考[J].中国当代医药,2010,17(34):6-8.
[36]王明明,郁晓维.脾虚证免疫学研究[J].吉林中医药,2011,31(11):1035-1037.
[37]严梅桢,李志军,谢念祥,等.四君子汤对实验性脾虚小鼠肠道菌群的影响[J].中国微生态学杂志,1989,1(1):40-43.
[38]杨旭东,张杰,王崴.参苓白术散对脾虚小鼠肠保护作用及其机制的研究[J].牡丹江医学院学报,2009,30(5):9-11.
[39]罗艳春,韩晶莉,罗艳秋,等.黄芪、白术、枳壳对大鼠肠道微生态失调的调整作用[J].中国老年学杂志,2009,29(12):1485-1487.
[40]江月斐,劳绍贤,邝枣园,等.腹泻型肠易激综合征脾胃湿热证肠道菌群的变化[J].中国中西医结合杂志,2006,26(3):218-220.
[41]江月斐,劳绍贤,邝枣园,等.清热化湿复方对腹泻型肠易激综合征脾胃湿热证肠道微生态影响的初步研究[J].福建中医学院学报,2008,18(4):1-4.
[42]XU J,LIAN F,ZHAO L,et al.Structural modulation of gut microbiota during alleviation of type 2 diabetes with a Chinese herbal formula[J].ISME J,2015,9(3):552-562.
[43]曾艺鹏,冯新格,谷成英,等.葛根芩连汤治疗对2型糖尿病湿热证肠道菌群影响[J].河北医学,2016,22(10):1731-1734.
[44]王婷,郑锋玲,骆欢欢.岭南温病湿热证小鼠模型的建立及肠道菌群的研究分析[J].中华中医药学刊,2017,35(6):1361-1365.
[45]刘芳,任平,李月彩,等.脾虚证大鼠胃、肠电-机械活动异常与CCK,SS含量变化的关系[J].第四军医大学学报,2001,22(10):881-884.
[46]王洪海,谢鸣.脾虚证模型大鼠血液流变学及TXB2、6-Keto-PGF1α的变化[J].北京中医药大学学报,2007,30(11):761-768.
[47]李艳彦,谢鸣,陈禹,等.肝郁脾虚证模型大鼠下丘脑-垂体-肾上腺皮质的变化[J].现代生物医学进展,2006,6(4):10-12.
[48]任平,刘芳,黄熙,等.脾虚大鼠生长抑素、胃动素、胆囊收缩素内分泌细胞的变化[J].成都中医药大学学报,2001,24(1):35-37.
[49]王洪海,谢鸣.复合病因造模法致脾虚证大鼠模型在免疫系统方面的变化[J].中国实验方剂学杂志,2006,12(12):41-45.
[50]赵丽,曲长江.脾虚与自由基[J].辽宁中医学院学报,2002,4(2):104-105.
[51]广州中医学院脾胃研究组生化小组.脾虚患者唾液淀粉酶活性初步研究[J].新中医,1978(3):45-47.
[52]修宗昌,余绍源,黄穗平.脾虚证临床诊断标准浅识[J].中医药学刊,2003,21(2):219-220.
[53]王晓明,易杰,廖世新,等.脾虚证动物模型的客观评估[J].中华中医药杂志,2006,21(7):406-408.
[54]沈华,关崇芬.蛋白酪氨酸激酶的ELISA测定方法及其在脾虚证研究中的应用[J].中国中西医结合杂志,1998,18(S1):243-245.
[55]任平,黄熙,李月彩,等.脾虚证大鼠组织和血浆中SS,CCK,Mot含量的变化[J].世界华人消化杂志,2000,8(4):436-438.
[56]杨泽民,陈蔚文,王颖芳.慢性浅表性胃炎脾虚证患者与健康人物质能量代谢基因差异表达研究[J].中国中西医结合杂志,2012,32(9):1180-1187.
[57]杨泽民,陈蔚文,王颖芳.慢性浅表性胃炎脾虚与脾胃湿热证患者物质能量代谢基因差异表达研究[J].中国中西医结合杂志,2013,33(2):159-163.
[58]吕凌.基于蛋白质组学的脾虚大鼠脾失健运机理的实验研究[D].沈阳:辽宁中医药大学,2012.
[59]崔海珍,陈家旭.亚健康脾虚证的尿液代谢组学研究[J].山东中医杂志,2011,30(7):468-470.
[60]吴云,陈瑞,田维毅.苦寒中药对肠道菌群结构影响的研究进展[J].中国微生态学杂志,2015,27(2):235-239.
[61]刘起胜,徐筱红,刘怀,等.七味白术散对菌群失调腹泻小鼠肠绒毛和隐窝的影响[J].中国中医药现代远程教育,2014,12(23):154-155.
[62]董开忠,高永盛,秦宁恩加,等.参苓白术散对抗生素引起肠道菌群失调小鼠的影响[J].中国实验方剂学杂志,2015,21(1):154-157.
[63]李吉武,唐爱华,赵伟,等.温阳益气活血方对肥胖2型糖尿病患者肠道菌群变化及脂质代谢的影响[J].中医杂志,2015,56(5):409-413.
基本信息:
DOI：10.13288/j.11-2166/r.2018.01.006
中图分类号:R259
引用信息:
[1]张北华,王凤云,卞兆祥,等.证候表型与肠道微生态的相关性[J],2018,59(01):21-25.DOI:10.13288/j.11-2166/r.2018.01.006.
基金信息:
国家自然科学基金(81403393,81173209,81373580)